Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (4642)	11/18/1999 1:45:00 PM
From: paper man	Respond to of 4891

<Disclaimer> Kingfisher. Hello and hope all is well. I admire your post and felt it important to share this with you and all supporters of Advanced Viral. It may not mean much today, but I am sure time will take the proper course. <Disclaimer> SALT LAKE CITY, Nov 18 (Reuters) - Myriad Genetics Inc. said Thursday that it has identified a novel drug target for the treatment of HIV that represents a new approach to treating AIDS. Myriad said that the new target may enable the creation of an entirely new class of therapeutics, distinct from the protease inhibitors or reverse-transcriptase inhibitors which are the most commonly prescribed among the current generation of HIV drugs. The target has not been licensed to another company and represents Myriad's seventh internal drug development program. Assays for drugs that modify the target have been created in preparation for high-throughput screening by Myriad Pharmaceuticals Inc., the company's wholly owned subsidiary. "This new HIV drug target is especially exciting in that it has the potential to improve on current treatments for AIDS," said Adrian Hobden, president of Myriad Pharmaceuticals, in a statement. "With the evolution of multi-drug resistant strains of the virus comes an increased need for therapies that act through different mechanisms," Hobden said. 08:01 11-18-99 <Disclaimer>